{"organizations": [], "uuid": "05957f283c7b2d997434f58c3f38682f8551e707", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180524.html", "section_title": "Archive News &amp; Video for Thursday, 24 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biotime-further-expands-opregen-cl/brief-biotime-further-expands-opregen-clinical-trial-in-dry-amd-with-the-opening-of-two-additional-u-s-sites-idUSASC0A3IR", "country": "US", "domain_rank": 408, "title": "BRIEF-BioTime Further Expands Opregen Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-05-24T19:24:00.000+03:00", "replies_count": 0, "uuid": "05957f283c7b2d997434f58c3f38682f8551e707"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biotime-further-expands-opregen-cl/brief-biotime-further-expands-opregen-clinical-trial-in-dry-amd-with-the-opening-of-two-additional-u-s-sites-idUSASC0A3IR", "ord_in_thread": 0, "title": "BRIEF-BioTime Further Expands Opregen Clinical Trial In Dry-AMD With The Opening Of Two Additional U.S. Sites", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "opregen", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biotime inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 24 (Reuters) - BioTime Inc:\n* BIOTIME FURTHER EXPANDS OPREGENÂ® CLINICAL TRIAL IN DRY-AMD WITH THE OPENING OF TWO ADDITIONAL U.S. SITES\n* BIOTIME INC - EXPANSION OF ONGOING PHASE I/IIA CLINICAL TRIAL FOR OPREGEN, WITH ADDITION OF TWO NEW U.S. SITES Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-24T19:24:00.000+03:00", "crawled": "2018-05-25T16:31:25.032+03:00", "highlightTitle": ""}